VIM and myxoma: The review article by Alvarado-Villacorta et al[15] reported that all immunohistochemically evaluated conjunctival myxomas showed extensive reactivity with vimentin (19/19, 100%), and most cases demonstrated strong and diffuse immunoreactivity for CD34 (18/20, 90%).